Sandoz begins Tavist-D cold indication television advertising week of Nov. 11.
This article was originally published in The Tan Sheet
Executive Summary
SANDOZ TAVIST-D COLD INDICATION ADVERTISING KICKS OFF NOV. 11 and continues the Tavist theme of highlighting 12-hour relief. Sandoz received FDA approval of a common cold indication for the antihistamine Tavist-1 and the antihistamine/decongestant Tavist-D on Oct. 31 ("The Tan Sheet" Nov. 4, In Brief). The products, which contain 1.34 mg clemastine fumarate, are the first antihistamines to carry the indication and the only OTCs that contain clemastine fumarate.